Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Who owns Sagimet Biosciences Inc. Series A Common Stock (SGMT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 96.4% of the shares are freely tradable; institutional investors hold 21.9%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.78 | 1,098,919 | +0.0 | 03/31/2026 |
| Woodline Partners LP | 1.62 | 1,000,943 | +0.0 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 1.56 | 966,253 | +23.8 | 03/31/2026 |
| Baker Bros Advisors LP | 1.54 | 952,996 | +0.0 | 03/31/2026 |
| Affinity Asset Advisors, LLC | 1.41 | 868,020 | -24.4 | 03/31/2026 |
| Millennium Management LLC | 1.40 | 862,303 | +46.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 3.01 | 1,861,227 | +139.0 | 06/30/2026 |
| iShares Russell 2000 ETF | 2.43 | 1,502,403 | +1.1 | 07/28/2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.58 | 975,281 | +0.6 | 07/29/2026 |
| abrdn Life Sciences Investors | 1.37 | 847,700 | +49.7 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Jul 2026 | Happel David | President & CEO | Sell | 64,051 | 7.76 | 497,068 |
| 20. Jul 2026 | Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 10,545 | 7.76 | 81,832 |
| 20. Jul 2026 | Kemble George | Director | Sell | 18,844 | 7.46 | 140,529 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.